Pfizer announced in a press release that “they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion.”  For further details about this acquisition, please visit: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira